title: Prostate cancer risk in pre-diabetic men: a matched cohort study.
abstract: BACKGROUND
  Diagnosis and duration of type 2 diabetes mellitus (DM) appear to be associated with decreased prostate cancer risk. Limitations of previous studies include methods of subject selection and accurate definition of DM diagnosis. We examined the temporal relationship between DM and prostate cancer risk exploring the period of greatest risk starting from the prediabetic to the post-diabetic period using clinical and administrative data to accurately define the date of DM diagnosis.
  
  
  METHODS
  We identified 5,813 men who developed DM between January 1, 1995 and December 31, 2009 (reference date, date of DM onset or matched date for non-diabetic cohort) and 28,019 non-diabetic men matched by age, smoking history, residence, and reference date. Prostate cancer incidence before and after the reference date was assessed using Cox regression modeling adjusted for matching variables, body mass index, insurance status, and comorbidities. Primary outcomes included hazard ratio (HR) and number needed to be exposed to DM for one additional person to be harmed (NNEH) or benefit (NNEB) with respect to prostate cancer risk.
  
  
  RESULTS
  After full adjustment, the HR for prostate cancer before DM diagnosis was 0.96 (95% CI 0.85-1.08; P=0.4752), and the NNEB was 974 at DM diagnosis. After the reference date, the fully-adjusted HR for prostate cancer in diabetic men was 0.84 (95% CI 0.72-0.97, P=0.0167), and the NNEB 3 years after DM onset was 425. The NNEB continued to decrease over time, reaching 63 at 15 years after DM onset, suggesting an increasing protective effect of DM on prostate cancer risk over time. No significant difference between the diabetic and non-diabetic cohort was found prior to reference date.
  
  
  CONCLUSIONS
  Prostate cancer risk is not reduced in pre-diabetic men but decreases after DM diagnosis and the protective effect of DM onset on prostate cancer risk increases with DM duration.
authors: Corresponding Author: Adedayo A. Onitilo, MSCR, FACP; Marshfield Clinic Weston Center; 3501 Cranberry Boulevard; Weston, WI 54476; . onitilo.adedayo@marshfieldclinic.org.
authors: Adedayo A
authors: AA
authors: Onitilo
authors: Richard L
authors: RL
authors: Berg
authors: Jessica M
authors: JM
authors: Engel
authors: Rachel V
authors: RV
authors: Stankowski
authors: Ingrid
authors: I
authors: Glurich
authors: Gail M
authors: GM
authors: Williams
authors: Suhail A R
authors: SA
authors: Doi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D048909:Diabetes Complications / Q000175:diagnosis; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000150:complications / Q000175:diagnosis*; D012307:Risk Factors; D013997:Time Factors
keywords: NNEH/NNEB; Prostatic neoplasms/epidemiology; Risk factors; Type 2 diabetes mellitus
references: J Urol. 2006 Oct;176(4 Pt 1):1524-7; discussion 1527-8
references: 16952672
references: Asian Pac J Cancer Prev. 2012;13(8):4097-100
references: 23098523
references: Prostate. 2009 Dec 1;69(16):1744-50
references: 19676082
references: Urology. 2012 Jun;79(6):1329-34
references: 22656412
references: Int J Cancer. 2009 Mar 15;124(6):1398-403
references: 19058180
references: J Clin Epidemiol. 1996 Jun;49(6):643-52
references: 8656225
references: Prostate. 2008 Jul 1;68(10):1126-32
references: 18459104
references: Exp Diabetes Res. 2012;2012:801610
references: 22792092
references: Int J Cancer. 2011 Feb 1;128(3):635-43
references: 20473855
references: CMAJ. 2005 Mar 1;172(5):613; author reply 613-5
references: 15738471
references: Metabolism. 2012 Feb;61(2):242-9
references: 21820134
references: Int J Cancer. 2011 Jan 15;128(2):440-6
references: 20473853
references: Diabetes Care. 2011 Mar;34(3):616-21
references: 21273499
references: Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
references: 20042775
references: Cancer Causes Control. 2007 Jun;18(5):493-503
references: 17450441
references: Cancer Causes Control. 2008 Sep;19(7):703-10
references: 18340542
references: Cancer Causes Control. 2011 Jul;22(7):977-83
references: 21562753
references: Diabetes Care. 2011 Jul;34(7):1669-75
references: 21709300
references: Cancer Causes Control. 1998 Jan;9(1):3-9
references: 9486458
references: JAMA. 2006 Mar 15;295(11):1288-99
references: 16537739
references: Clin Endocrinol (Oxf). 2013 Jul;79(1):100-4
references: 23153270
references: Eur J Cancer Prev. 2002 Apr;11(2):125-8
references: 11984129
references: Cardiovasc Diabetol. 2012 Oct 16;11:130
references: 23066943
references: Prostate Cancer Prostatic Dis. 2013 Jun;16(2):151-8, S1
references: 23032360
references: Cancer Causes Control. 2012 Jun;23(6):967-81
references: 22552844
references: Am J Epidemiol. 2005 Jan 15;161(2):147-52
references: 15632264
references: J Clin Endocrinol Metab. 2008 May;93(5):1834-40
references: 18319314
references: J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26
references: 8757191
references: Clin Med Res. 2009 Jun;7(1-2):4-13
references: 19574486
references: J Endourol. 2010 Jul;24(7):1123-9
references: 20575687